Distribution of funds for colorectal and cervical cancer screening programs in Spain

23

Sep 2022

On September 5, 2022, it was announced that the Interterritorial Council for the Spanish National Health System (CISNS) approved the distribution of funds to the Autonomous Communities for the fight against cancer. The aim is to boost the screening programs for colorectal and cervical cancer. It was outlined that these screenings are essential for the early detection of these pathologies in the target population. The total amount of funds to be distributed is €12 million, €6 million for 2022, and another €6 million for 2023.

As an example, the target population for colorectal cancer screening currently includes men and women aged 50 to 69 years. The screening test is a fecal occult blood test, and the interval between screening tests is two years. In addition to the screening program, in the case of people who meet the criteria of high personal risk or risk of familial or hereditary cancer, the assessment of the individual risk and follow-up is carried out through specific action protocols.

The target population for the cervical cancer screening program are women aged 25 to 65 years. In women aged 25 to 34 years the primary screening test is cytology, which is carried out every three years. In women aged 35 to 65 years, the determination of high-risk human papillomavirus (HPV) is used; further strategy depends on the test results. In addition to the screening program, in the case of women who meet the criteria of high personal risk or risk of familial or hereditary cancer, the assessment of the individual risk and follow-up is carried out through specific action protocols.

The full details in Spanish can be found here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

21

Sep 2022

In September 2022, Ordering Forum for New Methods has invited interested parties regarding electric field therapy (Optune, Tumor Treating Fields) alone or in combination with drugs for certain groups of glioblastoma patients, based on genome sequencing and biomarkers (indication II). Information should be submitted before November 8, 2022. Ordering Forum will be held on November 21, 2022, to decide whether the method will undergo evaluation at the national level.

Read more

15

Sep 2022

On August 25, 2022, the Norwegian Directorate of Health announced the launch of the National screening program for colorectal cancer (Bowel screening program - Tarmscreeningprogrammet). All 55-year-old men and women will be included in the program and offered a test to identify invisible blood in the stool (fecal immunochemical test, FIT) every two years until the age of 65. Colonoscopy will be offered in case of positive FIT.

Read more

13

Sep 2022

In August 2022, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (aortic remodeling hybrid stent insertion during surgical repair of aortic dissection, bioresorbable stent implantation to treat coronary artery disease, superficial venous arterialization for chronic limb ischemia, transcutaneous electrical neuromuscular stimulation for urinary incontinence, focal resurfacing implants to treat articular cartilage damage in the knee), and three new Medtech Innovation Briefings (Stockholm3 for prostate cancer screening, contrast-enhanced spectral mammography, differential target multiplexed spinal cord stimulation). Also, two Medical Technologies Guidance and two Medtech-related clinical guidelines were updated.

Read more

07

Sep 2022

On August 26, 2022, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning within the Orderly introduction framework for products that promote the transition to so-called “Close care” (Nära vård). Products of interest should enable diagnosis, treatment, and follow-up outside a healthcare facility, for example, remote monitoring. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until September 28, 2022.

Read more

02

Sep 2022

On August 01, 2022, a new version of the Nomenclature of Medical Biology Acts (NABM080) was released. One new code for the detection of the monkeypox virus genome was introduced.

Read more